Olivier Rascol

Olivier Rascol

UNVERIFIED PROFILE

Are you Olivier Rascol?   Register this Author

Register author
Olivier Rascol

Olivier Rascol

Publications by authors named "Olivier Rascol"

Are you Olivier Rascol?   Register this Author

100Publications

2696Reads

43Profile Views

Multiple System Atrophy: Recent Developments and Future Perspectives.

Mov Disord 2019 Nov 6. Epub 2019 Nov 6.

Services de Neurologie et de Pharmacologie Clinique, Centre de Reference AMS, Centre d'Investigation Clinique, Réseau NS-Park/FCRIN et Centre of Excellence for Neurodegenerative Disorders (COEN) de Toulouse, CHU de Toulouse, Toulouse 3 University, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27894DOI Listing
November 2019

Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort?

Parkinsonism Relat Disord 2019 Jul 25;64:226-234. Epub 2019 Apr 25.

Sorbonne Université, Assistance Publique Hôpitaux de Paris, Institut du Cerveau et de la Moelle épinière, ICM, Inserm U 1127, CNRS UMR 7225, Department of Neurology, Hôpital Pitié-Salpêtrière, F-75013, Paris, France; Center for Interdisciplinary Research in Biology, Collège de France, INSERM U1050, CNRS UMR7241, Labex Memolife, Paris Sciences et Lettres, Paris, France; AP-HP, Department of Neurology, Hôpital Avicenne, Hôpitaux Universitaires de Paris - Seine Saint Denis, Bobigny, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2019.04.012DOI Listing
July 2019

How to diagnose parkinsonian central pain?

Parkinsonism Relat Disord 2019 Jul 1;64:50-53. Epub 2019 May 1.

Department of Clinical Pharmacology and Neurosciences, Centre d'Investigation Clinique CIC1436, NS-Park/FCRIN Network, UMR ToNIC 1214, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2019.04.025DOI Listing
July 2019

Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type.

Parkinsonism Relat Disord 2019 Jun 5;63:199-203. Epub 2019 Feb 5.

Service de Neurologie, CRMR Atrophie Multisystématisée, CHU Bordeaux, 33000, Bordeaux, France; Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France; Dept. of Medicine, University of Otago, Christchurch, and New Zealand Brain Research Institute, Christchurch, New Zealand. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2019.02.006DOI Listing
June 2019

French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS).

Parkinsonism Relat Disord 2019 Jun 4;63:117-123. Epub 2019 Mar 4.

Université Clermont Auvergne, NPsy-Sydo, CHRU Clermont-Ferrand, NS-Park/F-CRIN Network, Neurology Department, Clermont-Ferrand, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2019.02.026DOI Listing
June 2019

Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's disease.

J Neural Transm (Vienna) 2019 Jun 16;126(6):789-793. Epub 2019 May 16.

Service de Neurologie, Hôpital Pellegrin, CHU de Bordeaux, 33000, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00702-019-02015-xDOI Listing
June 2019

Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases.

Expert Opin Pharmacother 2019 Apr 7;20(6):635-645. Epub 2019 Feb 7.

c Services de Pharmacologie Clinique et Neurosciences, Centre d'Investigation Clinique CIC 1436, NS-Park/FCRIN Network, NeuroToul COEN Center , Université de Toulouse UPS, CHU de Toulouse, INSERM , Toulouse , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574746DOI Listing
April 2019

Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial.

Parkinsonism Relat Disord 2019 03 4;60:51-56. Epub 2018 Oct 4.

Clinical Investigation Center CIC-1436, Departments of Clinical Pharmacology and Neurosciences, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse, France; F-CRIN, UMS 015, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2018.10.005DOI Listing
March 2019

Reversible myoclonus-ataxia encephalitis related to anti-mGLUR1 autoantibodies.

Mov Disord 2019 03 13;34(3):438-439. Epub 2019 Feb 13.

Department of Neurology, University Hospital of Toulouse, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27634DOI Listing
March 2019

CVT-301 for Parkinson's disease: dose and effect size issues.

Authors:
Olivier Rascol

Lancet Neurol 2019 Feb;18(2):128-130

Centre d'Investigation Clinique, Services de Neurologie et de Pharmacologie Clinique, Réseau NS-PARK/FCRIN et Centre COEN NeuroToul, Centre Hospitalier Universitaire de Toulouse, Institut National de la Santé et de la Recherche Médicale, University of Toulouse, 31300 Toulouse, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(18)30496-4DOI Listing
February 2019

Safety Profile of Opicapone in the Management of Parkinson's Disease.

J Parkinsons Dis 2019 ;9(4):733-740

Department of Research and Development, BIAL - Portela & Ca SA, S. Mamede do Coronado, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JPD-191593DOI Listing
January 2019

Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Nat Rev Drug Discov 2018 11 28;17(11):804-822. Epub 2018 Sep 28.

Centre d'Investigation Clinique CIC1436, Services de Neurologie et de Pharmacologie Clinique, Réseau NS-PARK/FCRIN et Centre COEN NeuroToul, CHU de Toulouse, INSERM, University of Toulouse 3, Toulouse, France.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/nrd.2018.136
Publisher Site
http://dx.doi.org/10.1038/nrd.2018.136DOI Listing
November 2018

Cannabis smoking impairs driving performance on the simulator and real driving: a randomized, double-blind, placebo-controlled, crossover trial.

Fundam Clin Pharmacol 2018 Oct 6;32(5):558-570. Epub 2018 Jun 6.

Aix-Marseille Université, CNRS, Institut des Sciences du Mouvement, UMR 7287, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/fcp.12382DOI Listing
October 2018

Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.

Mov Disord 2018 10 27;33(10):1528-1539. Epub 2018 Sep 27.

Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC 1436, NS-Park/FCRIN network and NeuroToul COEN Center, INSERM, CHU de Toulouse, Université de Toulouse 3, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27475DOI Listing
October 2018

Tamoxifen and the risk of Parkinsonism: a case/non-case study.

Eur J Clin Pharmacol 2018 Sep 3;74(9):1181-1184. Epub 2018 Jun 3.

Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, Université de Toulouse, 37 allées Jules-Guesde, 31000, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00228-018-2496-3DOI Listing
September 2018

Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.

J Neural Transm (Vienna) 2018 08 7;125(8):1237-1250. Epub 2018 Mar 7.

University of Toulouse 3, CHU of Toulouse, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00702-018-1869-1DOI Listing
August 2018

Longitudinal analysis of impulse control disorders in Parkinson disease.

Neurology 2018 07 20;91(3):e189-e201. Epub 2018 Jun 20.

From the Assistance Publique Hôpitaux de Paris (J.-C.C., F.C.-D., L.L., C.B., D.G., S.K., G.M., H.Y., A.B., M.V.); Sorbonne Université (J.-C.C., F.C.-D., L.L., C.B., D.G., S.K., G.M., H.Y., A.B., M.V.); INSERM (J.-C.C., F.C.-D., L.L., C.B., D.G., S.K., G.M., H.Y., A.B., M.V.), Institut du cerveau et de la Moelle, Centre d'Investigation Clinique Neurosciences, NS-PARK/FCRIN Network; CNRS (J.-C.C., F.C.-D., L.L., C.B., D.G., S.K., G.M., H.Y., A.B., M.V.); Departments of Neurology and Genetics (J.-C.C., F.C.-D., L.L., C.B., D.G., S.K., G.M., H.Y., A.B., M.V.), Hôpital Pitié-Salpêtrière, Paris; CESP (F.A., A.E.), Faculte de médecine, Université Paris-Sud; Faculte de médecine (F.A., A.E.), UVSQ, Institut National de la Santé et de la Recherche Médicale, Université Paris-Saclay, Villejuif; University of Toulouse 3 (O.R., C.B.-C., F.O.-M), Centre Hospitalo-Universitaire de Toulouse and INSERM; Centre d'Investigation Clinique CIC1436 (O.R., C.B.-C., F.O.-M), NS-PARK/FCRIN Network, Départements de Neurosciences et de Pharmacologie Clinique, NeuroToul COEN Center, Toulouse; Department of Neurology (F.D., A.-R.M.), NS-PARK/FCRIN Network, Centre Hospitalo-Universitaire de Clermont-Ferrand; Department of Neurology (P.D.), NS-PARK/FCRIN Network, Centre Hospitalo-Universitaire de Nantes; Department of Neurology (F.B.), Hôpital Foch, Suresnes; Department of Neurology (J.-P.B.), Fondation Rothschild, Paris; Department of Neurology (F.P.), Centre Hospitalier de Versailles; Université Versailles Saint Quentin en Yvelines et Paris Saclay (F.P.), Versailles; Department of Neurology (V.M.), Centre Hospitalo-Universitaire Saint-Antoine, Paris, France; and Department of Health Care Management (P.-C.L.), College of Health Technology, National Taipei University of Nursing and Health Sciences, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000005816DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059034PMC
July 2018

Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.

Neurology 2018 05 25;90(21):e1849-e1857. Epub 2018 Apr 25.

From the Instituto de Medicina Molecular (J.J.F.), Faculty of Medicine, University of Lisbon; CNS-Campus Neurológico Sénior (J.J.F.), Torres Vedras, Portugal; University College London (A.J.L.), Reta Lila Weston Institute, UK; Department of Neurology (W.P.), Medical University Innsbruck, Austria; Université de Toulouse (O.R.), CHU de Toulouse, Institut National de la Santé et de la Recherche Médicale, Department of Neurosciences and Clinical Pharmacology, Clinical Investigation Center 1436, and NeuroToul Center of Excellence in Neurodegeneration France; Department of Research and Development (J.-F.R., P.S.-d.-S.), BIAL-Portela & Ca SA, S. Mamede do Coronado, Portugal; Department of Biostatistics (B.K.), Clinipace Worldwide, Eschborn, Germany; and Department of Pharmacology and Therapeutics (P.S.-d.-S.), Faculty of Medicine, University Porto, Portugal.

View Article

Download full-text PDF

Source
http://www.neurology.org/lookup/doi/10.1212/WNL.000000000000
Publisher Site
http://dx.doi.org/10.1212/WNL.0000000000005557DOI Listing
May 2018

Combined cardiovascular and sweating autonomic testing to differentiate multiple system atrophy from Parkinson's disease.

Neurophysiol Clin 2018 Apr 14;48(2):103-110. Epub 2017 Dec 14.

Institut des maladies métaboliques et cardiovasculaires, université de Toulouse, CHU Rangueil, Toulouse, France; Pharmacology department, faculty of medicine Purpan, 37, allée Jules-Guesde, 31073 Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neucli.2017.11.003DOI Listing
April 2018

Iron as a therapeutic target for Parkinson's disease.

Mov Disord 2018 04 30;33(4):568-574. Epub 2018 Jan 30.

Université de Lille, CHU de Lille, INSERM UMRS_1171, Service de Pharmacologie Clinique et Service de Neurologie NS-Park/FCRIN Network LICEND COEN Center, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27275DOI Listing
April 2018

MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy.

Mov Disord 2018 04 23;33(4):600-608. Epub 2018 Feb 23.

ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27307DOI Listing
April 2018

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Neurology 2018 01 13;90(2):74-82. Epub 2017 Dec 13.

From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000004798DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772155PMC
January 2018

New perspectives on study designs for evaluating neuroprotection in Parkinson's disease.

Mov Disord 2017 10 13;32(10):1365-1370. Epub 2017 Jul 13.

Université de Lille, CHU de Lille, INSERM UMRS_1171, Service de Pharmacologie Clinique, CIC-CHU de Lille, NS-Park/FCRIN Network, LICEND COEN Center Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27055DOI Listing
October 2017

Critical appraisal of clinical trials in multiple system atrophy: Toward better quality.

Mov Disord 2017 Oct 7;32(10):1356-1364. Epub 2017 Aug 7.

Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27080DOI Listing
October 2017

Mortality and Antipsychotic Drug Use in Elderly Patients With Parkinson Disease in Nursing Homes.

J Am Med Dir Assoc 2017 Sep 13;18(9):791-796. Epub 2017 Jun 13.

Laboratoire de Pharmacologie Médicale et Clinique, CIC 1436, CHU de Toulouse, Inserm 1027, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jamda.2017.04.014DOI Listing
September 2017

Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA.

Expert Rev Neurother 2017 Jul 5;17(7):649-659. Epub 2017 Jun 5.

g Department of Neurology , Innsbruck Medical University , Innsbruck , Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2017.1336086DOI Listing
July 2017

Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.

Neurology 2017 Jun 10;88(23):2198-2206. Epub 2017 May 10.

From the Institute of Neurology (F.S.), IRCCS San Raffaele, Rome, Italy; Departments of Clinical Pharmacology and Neurosciences (O.R.), Clinical Investigation Center CIC1436, NS-Park Clinical Research Network, NeuroToul Centre of Excellence in Neurodegeneration, INSERM, Toulouse University Hospital and Toulouse University, France; Parkinson's Disease and Movement Disorders Center (R.A.H.), USF Health-Byrd Institute, Tampa, FL; and Merck & Co., Inc. (S.H., A.T., R.C., T.W.H., P.S., C.L., D.M., D.J.H.), Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000004003DOI Listing
June 2017

An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders.

Br J Clin Pharmacol 2017 03 6;83(3):612-622. Epub 2016 Nov 6.

Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.13145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306476PMC
March 2017

Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

JAMA Neurol 2017 Feb;74(2):197-206

Department of Research and Development, BIAL-Portela & Ca SA, Sao Mamede do Coronado, Portugal8Department of Pharmacology and Therapeutics, University Porto, Porto, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaneurol.2016.4703DOI Listing
February 2017

Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease.

Eur J Clin Pharmacol 2017 Jan 27;73(1):99-103. Epub 2016 Oct 27.

Laboratoire de Pharmacologie Médicale et Clinique de la Faculté de Médecine et du Centre Hospitalier Universitaire de Toulouse, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00228-016-2142-xDOI Listing
January 2017

The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.

Expert Rev Neurother 2016 19;16(3):245-58. Epub 2016 Feb 19.

b Department of Clinical Pharmacology and Neurosciences , NeuroToul Excellence Center for Neurodegenerative Disorders, University Hospital and University of Toulouse 3 , Toulouse , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737175.2016.1150783DOI Listing
December 2016

Unmasking levodopa resistance in Parkinson's disease.

Mov Disord 2016 11 19;31(11):1602-1609. Epub 2016 Jul 19.

Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26712DOI Listing
November 2016

Long-term effects of rasagiline and the natural history of treated Parkinson's disease.

Mov Disord 2016 10;31(10):1489-1496

Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26724DOI Listing
October 2016

Pharmacological Insights into Levodopa-induced Motor Fluctuations in Patients with Parkinson's Disease.

Authors:
Olivier Rascol

Mov Disord Clin Pract 2016 Nov-Dec;3(6):523-526. Epub 2016 Sep 4.

Clinical Investigation Center INSERM 1436 Department of Clinical Pharmacology and Neurosciences University Hospital of Toulouse UMR Tonic 1214, University of Toulouse III Toulouse France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12389DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178700PMC
September 2016

Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.

CNS Drugs 2016 08;30(8):703-17

Department of Clinical Pharmacology and Neurosciences and NeuroToul Center of Excellence in Neurodegeneration (COEN), University Hospital and University of Toulouse III, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40263-016-0360-5DOI Listing
August 2016

Atropinic (Anticholinergic) Burden in Parkinson's Disease.

Mov Disord 2016 05 29;31(5):632-6. Epub 2016 Mar 29.

Service de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire et Faculté de Médecine de Toulouse, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26595DOI Listing
May 2016

Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease.

Mov Disord 2016 Mar 17;31(3):325-34. Epub 2015 Dec 17.

INSERM, Imagerie Cérébrale et Handicaps Neurologiques, UMR 825, 31059, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26471DOI Listing
March 2016

Espresso Coffee for the Treatment of Somnolence in Parkinson's Disease: Results of n-of-1 Trials.

Front Neurol 2016 8;7:27. Epub 2016 Mar 8.

Departments of Clinical Pharmacology and Neurosciences, University Hospital of Toulouse and Clinical Investigation Center INSERM CIC9302 and UMR825, University of Toulouse III , Toulouse , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2016.00027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782159PMC
March 2016

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.

Lancet Neurol 2016 02 23;15(2):154-165. Epub 2015 Dec 23.

Department of Research and Development, BIAL-Portela and Ca SA, S Mamede do Coronado, Portugal; Department of Pharmacology and Therapeutics, Faculty of Medicine, University Porto, Porto, Portugal; MedInUP, Center for Drug Discovery and Innovative Medicines, University Porto, Porto, Portugal. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(15)00336-1DOI Listing
February 2016

Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia.

Neurology 2016 Feb 20;86(7):651-9. Epub 2016 Jan 20.

From the Centre d'Investigation Clinique, Department of Neurology (H.P.-C., T.R., P. Damier), Department of Medical Evaluation and Epidemiology (J.-M.N.), and Department of Neurosurgery (S.R.), CHU Nantes, INSERM; Hôpital Neurologique (S.T., C.L., P.M.), Hospices Civils de Lyon, Université de Lyon 1; Centre d'Investigation Clinique, Department of Neurology (C.B.-C., F.O.-M., O.R.), CHU Toulouse, INSERM; Departments of Psychiatry (I.C.) and Neurology (P. Derost, M.U.), CHU Clermont-Ferrand; Departments of Neurosurgery (E.C.) and Neurology (D.G., P.B.), Bordeaux CHU; and the Departments of Neurology (A.E., T.W.) and Neurosurgery (J.R.), Assistance Publique Hôpitaux de Marseille, France.

View Article

Download full-text PDF

Source
http://www.neurology.org/content/early/2016/01/20/WNL.000000
Web Search
http://www.neurology.org/cgi/doi/10.1212/WNL.000000000000237
Publisher Site
http://dx.doi.org/10.1212/WNL.0000000000002370DOI Listing
February 2016

Distinctive features of NREM parasomnia behaviors in parkinson's disease and multiple system atrophy.

PLoS One 2015 10;10(3):e0120973. Epub 2015 Mar 10.

Brain Function & Neuromodulation, Grenoble Institute of Neuroscience, Grenoble, France; Joseph Fourier University, Grenoble, France.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0120973PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355286PMC
November 2015

Subjective sleep dysfunction and insomnia symptoms in Parkinson's disease: Insights from a cross-sectional evaluation of the French CoPark cohort.

Parkinsonism Relat Disord 2015 Nov 10;21(11):1323-9. Epub 2015 Sep 10.

Department of Clinical Pharmacology, Paul Sabatier University and Toulouse University Hospital, Toulouse, France; INSERM UMR825 Neuroimaging and Neurologic Diseases, Toulouse, France; Centre d'Investigation Clinique CIC 9302, Toulouse University Hospital, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2015.09.025DOI Listing
November 2015

Falls in ambulatory non-demented patients with Parkinson's disease.

J Neural Transm (Vienna) 2015 Oct 7;122(10):1447-55. Epub 2015 Apr 7.

NS-Park Network, INSERM, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00702-015-1396-2DOI Listing
October 2015

Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.

J Am Med Dir Assoc 2015 Oct 1;16(10):898.e1-7. Epub 2015 Aug 1.

Institute of Neuroscience, Newcastle University, Newcastle, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jamda.2015.06.021DOI Listing
October 2015

New treatments for levodopa-induced motor complications.

Mov Disord 2015 Sep 21;30(11):1451-60. Epub 2015 Aug 21.

Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26362DOI Listing
September 2015

Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial.

Lancet Neurol 2015 Feb 8;14(2):145-52. Epub 2014 Dec 8.

Clinical Investigation Center CIC1436, Departments of Clinical Pharmacology and Neurosciences, INSERM and University Hospital of Toulouse, Faculty of Medicine, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(14)70288-1DOI Listing
February 2015

Parkinson's disease and local atrophy in subcortical nuclei: insight from shape analysis.

Neurobiol Aging 2015 Jan 23;36(1):424-33. Epub 2014 Jul 23.

INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU PURPAN, Toulouse, France; Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU PURPAN, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurobiolaging.2014.07.010DOI Listing
January 2015

Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.

Parkinsonism Relat Disord 2014 Sep 14;20(9):947-56. Epub 2014 May 14.

Novartis Institutes for Biomedical Research, Basel, Switzerland; Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2014.05.003DOI Listing
September 2014

Parkinson disease: Can a new trial end controversy over when to use levodopa?

Authors:
Olivier Rascol

Nat Rev Neurol 2014 Sep 19;10(9):488-9. Epub 2014 Aug 19.

Clinical Investigation Centre CIC1436, Departments of Clinical Pharmacology and Neurosciences, INSERM and Toulouse University Hospital, University of Toulouse 3, Place du Docteur Baylac, TSA 40031, 31059 Toulouse CEDEX 9, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrneurol.2014.147DOI Listing
September 2014

Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies.

Neurobiol Dis 2014 Jul 12;67:133-9. Epub 2014 Apr 12.

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France; Service de Neurologie, CHU de Bordeaux, F-33604 Pessac, France; Centre de référence atrophie multisystématisée, CHU de Bordeaux, Pessac, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2014.03.021DOI Listing
July 2014

Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.

JAMA Neurol 2014 Jul;71(7):884-90

Department of Clinical Pharmacology, Faculty of Medicine, University Hospital, University of Toulouse, Toulouse, France2Department of Neurosciences, University Hospital, University of Toulouse, Toulouse, France3Clinical Investigation Center 1436, Universi.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaneurol.2014.753DOI Listing
July 2014

The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model.

Mov Disord 2014 Jul 27;29(8):1074-9. Epub 2014 May 27.

Motac neuroscience, Manchester, UK; Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Service de Neurologie, CHU de Bordeaux, Pessac, France; Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25920DOI Listing
July 2014

A cross-sectional study on drug use in multiple system atrophy.

CNS Drugs 2014 May;28(5):483-90

Departments of Clinical Pharmacology and Neurosciences, Faculty of Medicine, University Hospital and University of Toulouse 3, 37 Allées Jules Guesde, 31000, Toulouse, France,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40263-014-0159-1DOI Listing
May 2014

Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients.

Expert Opin Drug Saf 2014 Mar;13(3):351-60

Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences , Toulouse , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740338.2014.888057DOI Listing
March 2014

Jejunal levodopa infusion in Parkinson's disease.

Authors:
Olivier Rascol

Lancet Neurol 2014 Feb 20;13(2):128-9. Epub 2013 Dec 20.

Clinical Investigation Center CIC-9302, NS-Park Network and Departments of Clinical Pharmacology and Neurosciences, INSERM, Toulouse University Hospital and University Paul Sabatier Toulouse III, Toulouse, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(13)70291-6DOI Listing
February 2014

Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.

Neurology 2014 Jan 26;82(4):300-7. Epub 2013 Dec 26.

From INSERM, Clinical Investigation Center 9302 (F.O.-M., C.B.-C., E.D., M.G., C.T., A.S., O.R.), and Department of Neurology (F.O.-M., C.B.-C., O.R.), University Hospital of Toulouse; INSERM, Clinical Investigation Center 9503 (J.-C.C., A.-M.B., M.V.), and AP-HP, Department of Neurology (J.-C.C., A.-M.B., M.V.), Pitié-Salpêtrière Hospital, Paris; CRICM UPMC/INSERM UMR_S975 CNRS UMR7225 (J.-C.C., M.V.), Institut de la Moelle et du Cerveau, Université Pierre Marie Curie Paris-6, Salpêtrière, Paris; AP-HM (J.-P.A.), Department of Neurology, Timone Hospital, Marseille; Department of Clinical Pharmacology (C.B.-C., C.T., A.S., O.R.), University of Medicine, Toulouse; INSERM (C.B.-C., O.R.), and Université de Toulouse, UPS (C.B.-C., O.R.), Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse; Department of Neurology (P.D., T.L.), University Hospital of Nantes; Department of Neurology (A.D.), University Hospital of Lille; Department of Neurology (F.D.), University Hospital of Clermont-Ferrand; Department of Neurology (W.M., F.T.), University Hospital of Bordeaux; and Department of Neurology (F.V.), Pays-d'Aix Hospital, Aix-en-Provence, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000000050DOI Listing
January 2014

Physical exercise in Parkinson disease: moving toward more robust evidence?

Authors:
Olivier Rascol

Mov Disord 2013 Aug 15;28(9):1173-5. Epub 2013 Apr 15.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25453DOI Listing
August 2013

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.

Mov Disord 2013 Jul 29;28(8):1064-71. Epub 2013 Apr 29.

Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25364DOI Listing
July 2013

Nociceptive brain activation in patients with neuropathic pain related to Parkinson's disease.

Parkinsonism Relat Disord 2013 May 23;19(5):548-52. Epub 2013 Feb 23.

Inserm, Imagerie cérébrale et handicaps neurologiques, UMR 825, F-31059 Toulouse, France - Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, F-31059 Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2013.02.003DOI Listing
May 2013

Extended-release carbidopa-levodopa in Parkinson's disease.

Authors:
Olivier Rascol

Lancet Neurol 2013 Apr 26;12(4):325-6. Epub 2013 Feb 26.

CIC-9302/INSERM UMR825, Departments of Clinical Pharmacology and Neurosciences, University UPS of Toulouse III, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(13)70039-5DOI Listing
April 2013

Emerging drugs for autonomic dysfunction in Parkinson's disease.

Expert Opin Emerg Drugs 2013 Mar 1;18(1):39-53. Epub 2013 Feb 1.

University of Toulouse III, University Hospital, Department of Clinical Pharmacology and Neuroscience, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728214.2013.766168DOI Listing
March 2013

Which dyskinesia scale best detects treatment response?

Mov Disord 2013 Mar 6;28(3):341-6. Epub 2013 Feb 6.

Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25321DOI Listing
March 2013

Rotigotine transdermal patch for the treatment of Parkinson's Disease.

Fundam Clin Pharmacol 2013 Feb 9;27(1):81-95. Epub 2012 Feb 9.

Departments of Clinical Pharmacology and Neurosciences, University Hospital, University of Toulouse, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1472-8206.2012.01028.xDOI Listing
February 2013

Trial designs used to study neuroprotective therapy in Parkinson's disease.

Mov Disord 2013 Jan 23;28(1):86-95. Epub 2012 Aug 23.

Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.24997DOI Listing
January 2013

Drugs associated with restless legs syndrome: a case/noncase study in the French Pharmacovigilance Database.

J Clin Psychopharmacol 2012 Dec;32(6):824-7

Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire et Université Paul Sabatier, Faculté de Médicine, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCP.0b013e318272cdd8DOI Listing
December 2012

Effect of subthalamic deep brain stimulation on pain in Parkinson's disease.

Pain 2012 Nov 7;153(11):2267-73. Epub 2012 Sep 7.

INSERM, Imagerie cérébrale et handicaps neurologiques, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pain.2012.07.026DOI Listing
November 2012

Factors related to orthostatic hypotension in Parkinson's disease.

Parkinsonism Relat Disord 2012 Jun 13;18(5):501-5. Epub 2012 Feb 13.

Laboratoire de Pharmacologie Médicale et Clinique, INSERM U 1027 Equipe de PharmacoEpidémiologie, l'Université de Toulouse, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2012.01.012DOI Listing
June 2012

Emerging analgesic drugs for Parkinson's disease.

Expert Opin Emerg Drugs 2012 Jun 25;17(2):157-71. Epub 2012 Apr 25.

University Hospital and University Paul Sabatier Toulouse 3, Departments of Clinical Pharmacology and Neurosciences, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728214.2012.677949DOI Listing
June 2012

Parkinson disease: Serotonin reuptake inhibitors for depression in PD.

Nat Rev Neurol 2012 Jun 5;8(7):365-6. Epub 2012 Jun 5.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrneurol.2012.111DOI Listing
June 2012